ADVERTISEMENT

Alkeus Pharmaceuticals names Seemi Khan as chief medical officer

Before joining the company, Dr Khan served as chief medical officer at Reata Pharmaceuticals

Alkeus Pharmaceuticals / Image: Alkeus Pharmaceuticals

Massachusetts-based biopharmaceutical company Alkeus Pharmaceuticals, Inc has appointed Dr Seemi Khan as its chief medical officer.

Reacting to the appointment, Khan said she was looking forward to joining Alkeus, particularly at a time “when Gildeuretinol (ALK-001) has shown promising advancement toward the treatment of Stargardt disease."



Leonide Saad, president and CEO at Alkeus Pharmaceuticals, welcomed Khan to the Alkeus executive team to innovate transformative therapies for degenerative eye diseases.

“An accomplished executive, Dr Khan has a track record in bringing rare disease treatments to patients in need across multiple therapeutic areas,” Saad said.

Khan expressed eagerness to build the team to bring a significant impact on the lives of individuals struggling with vision loss. "My commitment to medical innovation and patient care aligns seamlessly with Alkeus' mission, and I look forward to driving forward this life-changing treatment,” she added.

Before joining Alkeus Pharmaceuticals, Khan served as chief medical officer at Reata Pharmaceuticals through its acquisition by Biogen, where she oversaw all clinical programs from early stage to commercialization.

She was also instrumental in the approval and launch of the first treatment for Friedreich’s ataxia. Her experience also includes senior leadership roles at Mitsubishi Tanabe Pharma America, Quark Pharmaceuticals, Abbott, and AbbVie.

A nephrologist with expertise in rare diseases, immunology and rheumatology, she has served as an assistant professor of medicine at Tufts University School of Medicine. She completed her post-graduation in Public Health from Harvard T.H. Chan School of Public Health and MBA from Brandeis University.

Meanwhile, Alkeus Pharmaceuticals, co-founded by Leonide Saad and Ilyas Washington, is focused on developing therapies for serious diseases of the eye. Its lead candidate gildeuretinol (ALK-001) is currently evaluated in clinical trials for the treatment of Stargardt disease, a rare genetic eye disease, and for geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Comments